Are stem cells proven to help autism?

There is no reliable basis for promising benefit to an individual child. Findings depend on the product and study design. MSCs and exosomes cannot be treated as equivalent to cord blood; each intervention needs its own evaluation.

Can a route or home exosome course be chosen in advance?

This page does not recommend such regimens. Each product and route needs its own evidence, risk assessment and basis for use. A small intravenous MSC study does not establish the safety of intrathecal injections or nasal exosomes.

Should support or medicines be stopped for the trip?

Do not stop prescribed care or medicines on your own. Discuss continuity of support, sleep, nutrition and travel safety with the treating clinician. Epilepsy and other coexisting conditions need individual assessment; this website cannot confirm eligibility for an intervention.

HU · HAN'S UNITED · CLINICAL ARCHIVEFOUNDED 2007 · SHANGRAO

Dossier №

002

/ 010

─── Neurology

Stem cells for autism in China: what is known

Abstract

Stem cells for autism in China: research findings, limitations and questions before travelling to Shangrao. What to discuss with a clinician and which records to prepare.

Cell-based interventions for ASD remain investigational. Speech development, behavioural change or an autism ‘cure’ cannot be promised. A travel decision needs to account for uncertain benefits and risks of the specific intervention.

Get a consultation All treatments · Neurology

Supporting the child and the family’s goals

Autism support is tailored to the child’s communication, daily participation, sleep, learning and coexisting conditions. NICE recommends adapted social-communication interventions involving parents or teachers. This guidance describes ASD support, not the Han’s United programme; a cell intervention should not replace the care the child needs.

National Institute for Health and Care Excellence · 2013 · NICE guideline CG170

What cell studies show

Trials examine different products, including cord blood and mesenchymal stromal cells from cord tissue. These are not interchangeable. A large placebo-controlled cord-blood trial did not establish an overall social-communication benefit. A small uncontrolled MSC study primarily examined tolerability. These findings cannot be transferred to every product, administration route or centre’s programme.

Positive signals: which children were studied

A small 2026 placebo-controlled trial of cord-blood mononuclear cells in children with ASD and immune dysregulation reported a positive SRS-2 signal. Its selected population, different cell product and short follow-up matter. This supports further research, not a promise of benefit for every autistic child.

Zhang Z, Wang G, Han F, et al. · 2026 · Stem Cell Research & Therapy

What cannot yet be predicted

These data cannot predict an individual child’s chance of benefit, a ‘best age’, number of procedures or time to speech development. A score change after a course does not by itself prove a cell effect: development, ongoing support and assessment methods also matter. A family’s account or video describes experience but cannot replace a controlled comparison.

What to establish before consent

Request the exact product and source, the basis for its use in ASD, quality documentation and specific risks. A trial should provide its registration, ethics approval and follow-up arrangements. Registration alone does not prove efficacy. Discuss the documents with an independent clinician before paying or travelling.

International Society for Stem Cell Research · 2024 · ISSCR patient guide

Records for discussing a trip to Shangrao

For a case discussion, gather existing specialist reports, developmental and skill-loss history, current support, medicines, allergies and seizure history. Include available investigations and developmental assessments. This is preparation for discussion, not a request to arrange MRI, EEG or laboratory tests yourself; a clinician determines whether new tests are needed. Links below provide the Shangrao contact details and enquiry process.

Costs and length of stay

This page does not quote a fixed price for an ‘autism course’. Before a travel decision, obtain an itemised written estimate for medical services, investigations, accommodation, interpretation and assistance. Clarify inclusions and who pays for complication care and follow-up after returning home. The site price page provides general information; applicability to the individual child needs separate confirmation.

Clinical evidence

Studies and clinical guidance

The study designs and limits of their findings are described below. A publication about a cell product does not automatically establish the efficacy of a particular centre’s programme.

Landmark study01

The Journal of Pediatrics2020

Dawson G, Sun JM, Baker J, et al.

Dawson G, Sun JM, Baker J, et al. A Phase II Randomized Clinical Trial of the Safety and Efficacy of Intravenous Umbilical Cord Blood Infusion for Treatment of Children with Autism Spectrum Disorder. J Pediatr. 2020;222:164-173.e5.

Double-blind RCT, 180 children: cord blood did not improve the primary social-communication outcome in the overall sample at 6 months. Subgroup signals need confirmation. The study tested cord blood, not MSCs or exosomes.

DOI: 10.1016/j.jpeds.2020.03.011

Show 4 more publications

02Stem Cell Research & Therapy2026
Zhang Z, Wang G, Han F, et al.
Zhang Z, Wang G, Han F, et al. UCB-MNCs in children with ASD and immune dysregulation: randomized placebo-controlled trial. Stem Cell Res Ther. 2026;17:301.
Single-centre double-blind RCT: 34 children analysed, limited to ASD with immune dysregulation. The authors reported SRS-2 improvement after UCB-MNCs at 13 weeks. The small selected sample and short follow-up prevent generalisation to all children, MSCs or exosomes.
DOI: 10.1186/s13287-026-05091-5
03Stem Cells Translational Medicine2020
Sun JM, Dawson G, Kurtzberg J, et al. (Duke)
Sun JM, Dawson G, Kurtzberg J, et al. Infusion of human umbilical cord tissue mesenchymal stromal cells in children with autism spectrum disorder. Stem Cells Transl Med. 2020;9(10):1137-1146.
Open-label phase I, 12 children, no control group. It assessed IV hCT-MSC tolerability; five participants developed new anti-HLA antibodies. Observed behavioural changes do not establish efficacy or rule out rare risks.
DOI: 10.1002/sctm.19-0434
04NICE guideline CG1702013
National Institute for Health and Care Excellence
NICE. Autism spectrum disorder in under 19s: support and management. Clinical guideline CG170.
Guidance on individual support, communication and coexisting conditions in ASD. It covers care for children and young people, not evidence of cell-intervention efficacy.
Open the publication
05ISSCR patient guide2024
International Society for Stem Cell Research
International Society for Stem Cell Research. The ISSCR Guide to Stem Cell Treatments. February 2024.
Questions about evidence, risks, consent and costs when considering a cell intervention.
Open the publication

This overview of published evidence is for discussion with a clinician. It is not an individual prescription or confirmation of eligibility for a cell intervention.

FAQ

Frequent questions on the diagnosis

01
Cerebral palsy
Stem cells for cerebral palsy in China: research findings, the role of rehabilitation and limitations. Records and cost questions before travelling to Shangrao.

All therapies in Neurology